Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Search markets
Search icon A magnifying glass. It indicates, "Click to perform a search".
Close icon Two crossed lines that form an 'X'. It indicates a way to close an interaction, or dismiss a notification.

QIAGEN N.V. Stock , QGEN

43.31 -0.24 -0.55%
10:40:59 AM BTT
Plus500. 82% of retail CFD accounts lose money
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar

On Friday morning 10/04/2024 the QIAGEN N.V. share started trading at the price of $43.38. Compared to the closing price on Thursday 10/03/2024 on BTT of $43.55, this is a drop of 0.39%. There are 221.85 M shares outstanding in QIAGEN N.V., which values the company at $8.50 B.

QIAGEN Stock Snapshot

43.29
Bid
200.00
Bid Size
43.35
Ask
14.00
Ask Size
10/4/2024
Date
10:40 AM
Time
6,210.00
Volume
43.55
Prev. Close
43.38
Open
9.96 B
Market Cap in USD
221.85 M
Number of Shares
221.85 M
Total Number of Shares
43.08
Day Low
43.52
Day High
43.31
35.81
52 Week Low
47.44
52 Week High
43.31
0.00
Dividend in USD
0.00
Dividend Yield
29.35
P/E Ratio
99.72
Free Float in %
1.54
EPS in USD
16.81
Book Value per Share in USD
2.05
Cash Flow per Share in USD
Start Trading Futures

Historical Prices for QIAGEN

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

QIAGEN Analyst Data

Total Analysts: 16
Buy Ratings: 12 Neutral Ratings: 4 Sell Ratings: 0
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 42.00 Median: 51.44 Highest: 60.00
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.

QIAGEN Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price
06/27/24 Wolfe Research
Upgraded to Buy $50
06/18/24 J.P. Morgan
Maintained Buy $54
05/01/24 Stifel, Nicolaus & Co., Inc.
Maintained Buy $45
02/16/24 Morgan Stanley
Upgraded to Buy $51
02/08/24 J.P. Morgan
Maintained Buy $52
02/08/24 Citigroup Corp.
Maintained Buy $60
12/20/23 J.P. Morgan
Maintained Buy $50
12/19/23 Wells Fargo & Co
Maintained Hold $44
12/13/23 Wolfe Research
Maintained Hold
12/07/23 Goldman Sachs
Upgraded to Buy
11/02/23 UBS
Maintained Hold $42
10/17/23 J.P. Morgan
Maintained Buy $50
09/26/23 Citigroup Corp.
Maintained Buy $60
09/12/23 Baird Patrick & Co
Maintained Buy $50
08/09/23 UBS
Maintained Hold $48
02/09/23 UBS
Maintained Hold $52
02/09/23 Citigroup Corp.
Maintained Buy $60
11/09/22 Citigroup Corp.
Maintained Buy $55

QIAGEN Estimates* in USD

  2024 2025 2026 2027 2028
Revenue 1,975 2,089 2,230 2,381 2,554
Dividend - - 0.00 0.00 0.00
Dividend Yield (in %) 0.00 % 0.00 % 0.00 % 0.00 % 0.00 %
EPS 2.15 2.29 2.52 2.73 2.99
P/E Ratio 20.66 19.35 17.58 16.25 14.83
EBIT 562 605 657 713 771
EBITDA 722 773 839 871 935
Net Profit 480 509 555 594 637
Net Profit Adjusted 480 509 555 594 637
Pre-Tax Profit 599 629 680 745 808
Pre-Tax Profit Reported - - - 690 749
EPS (Non-GAAP) ex. SOE 2.14 2.28 2.42 - -
EPS (GAAP) 0.50 1.99 2.24 2.51 2.75
Gross Income 1,327 1,420 1,526 1,682 1,794
Cash Flow from Investing -52 -166 -176 - -
Cash Flow from Operations 507 572 689 - -
Cash Flow from Financing -548 -283 -167 - -
Cash Flow per Share - 2.83 - 3.19 3.38
Free Cash Flow 359 442 541 609 -
Free Cash Flow per Share - - - - -
Book Value per Share 16.89 18.64 20.59 21.39 24.12
Net Debt 448 105 -333 -988 -845
Research & Development Exp. 196 206 216 228 240
Capital Expenditure 161 170 176 169 171
Selling, General & Admin. Exp. 568 594 620 658 689
Shareholder’s Equity 3,764 4,096 4,497 4,659 5,254
Total Assets 5,838 6,026 6,424 - -
  Previous Quarter
ending 09/30/24 		Current Quarter
ending 12/31/24 		Next Quarter
ending 03/31/25 		Current Year
ending 12/31/24 		Next Year
ending 12/31/25
Earnings Estimates
No. of Analysts 11 11 9 19 19
Average Estimate 0.544 USD 0.599 USD 0.489 USD 2.146 USD 2.291 USD
Year Ago 0.352 USD 0.441 USD 0.360 USD 1.542 USD -
Publish Date 10/30/2024 2/11/2025 5/5/2025 - -
Revenue Estimates
No. of Analysts 11 - 7 18 18
Average Estimate 491 USD - 483 USD 1,975 USD 2,089 USD
Year Ago 476 USD - 459 USD 1,965 USD -
Publish Date 10/30/2024 - 5/5/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. USD

2023 2022 2021 2020 2019 2018 2017
Sales 1,965.31 2,141.52 2,251.66 1,870.35 1,526.42 1,501.85 1,417.54
Change of sales in % -8.23 -4.89 20.39 22.53 1.64 5.95 5.95
Gross profit on sales 1,222.92 1,370.03 1,432.28 1,211.90 975.29 965.85 887.57
Gross profit on sales change in % -10.74 -4.35 18.18 24.26 0.98 8.82 8.10
Operating income 445.25 576.23 657.85 537.47 313.67 298.92 215.24
Operating income change in % -22.73 -12.41 22.40 71.35 4.94 38.88 12.35
Income before tax 429.81 512.60 625.83 439.47 -77.78 225.74 114.38
Income before tax change in % -16.15 -18.09 42.41 - - 97.37 100.98
Income after tax 341.30 423.21 512.60 359.19 -41.46 190.38 40.39
Income after tax change in % -19.35 -17.44 42.71 - - 371.31 -49.76

Balance Sheet in Mio. USD

2023 2022 2021 2020 2019 2018 2017
Total liabilities 2,307.43 2,821.12 3,050.40 3,114.69 2,699.03 3,113.36 2,497.52
Long-term liabilities per share 5.42 8.36 6.96 11.30 7.91 9.79 9.89
Equity 3,807.76 3,466.61 3,096.55 2,797.84 2,536.59 2,634.97 2,541.00
Equity change in % 9.84 11.95 10.68 10.30 -3.73 3.70 -2.54
Balance sheet total 6,115.19 6,287.74 6,146.95 5,912.53 5,235.62 5,748.33 5,038.52
Balance sheet total change in % -2.74 2.29 3.96 12.93 -8.92 14.09 16.95

Key Data in USD

2023 2022 2021 2020 2019 2018 2017
Sales per share 8.79 9.59 10.00 8.23 6.94 6.63 6.27
P/E ratio (year end quote, basic EPS) 29.35 27.12 25.16 34.46 - 42.25 181.90
P/E ratio (year end quote, diluted EPS) 29.35 27.12 25.16 34.46 - 42.25 181.90
P/E ratio (year end quote) 29.35 27.12 25.16 34.46 - 42.25 181.90
Dividend yield in % 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Equity ratio in % 62.27 55.13 50.38 47.32 48.45 45.84 50.43
Debt ratio in % 37.73 44.87 49.62 52.68 51.55 54.16 49.57

QIAGEN Dividend Calendar

Date Name Dividend *yield Currency
2023 QIAGEN N.V. 0.00 0.00 USD
2022 QIAGEN N.V. 0.00 0.00 USD
2021 QIAGEN N.V. 0.00 0.00 USD
2020 QIAGEN N.V. 0.00 0.00 USD
2019 QIAGEN N.V. 0.00 0.00 USD
2018 QIAGEN N.V. 0.00 0.00 USD
2017 QIAGEN N.V. 0.00 0.00 USD
2016 QIAGEN N.V. 0.00 0.00 USD
2015 QIAGEN N.V. 0.00 0.00 USD
2014 QIAGEN N.V. 0.00 0.00 USD
2013 QIAGEN N.V. 0.00 0.00 USD
2012 QIAGEN N.V. 0.00 0.00 USD
2011 QIAGEN N.V. 0.00 0.00 USD
2010 QIAGEN N.V. 0.00 0.00 USD
2009 QIAGEN N.V. 0.00 0.00 USD
*Yield of the Respective Date

QIAGEN Calendar

Event Estimate Info Date
Earnings Report 0.544 USD Q3 2024 Earnings Release 10/30/2024
Earnings Report 0.599 USD Q4 2024 Earnings Release 02/11/2025
Earnings Report 0.489 USD Q1 2025 Earnings Release 05/05/2025
Earnings Report 0.564 USD Q2 2025 Earnings Release 07/30/2025

QIAGEN Past Events

Event Actual EPS Info Date
Earnings Report -0.826 USD Q2 2024 Earnings Release 07/31/2024

QIAGEN Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.

QIAGEN Shareholder

Owner in %
Freefloat 99.72
Massachusetts Financial Services Co. 10.85
Massachusetts Financial Services Co. 10.46
Capital Research & Management Co. (International Investors) 3.36
Norges Bank Investment Management 2.94
Wellington Management International Ltd. 2.87
Government Pension Fund - Global (The) 2.85
Vanguard Group, Inc. (Subfiler) 2.78
Amundi Asset Management 2.54
Nuance Investments LLC 2.38
American Funds Growth Fund of America 2.13
UBS Asset Management (Americas) LLC 2.04
Wellington Management Co. LLP (Wellington Breakout) 1.99
Pendal Group Ltd. 1.94
Norges Bank (13F) 1.89
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.

QIAGEN Management

Name Job
Lawrence A. Rosen Chairman-Supervisory Board
Thierry Bernard Chief Executive Officer & Managing Director
Roland Sackers Chief Financial Officer & Managing Director
Stephen H. Rusckowski Independent Member-Supervisory Board
Elizabeth E. Tallett Independent Member-Supervisory Board
Elaine R. Mardis Independent Member-Supervisory Board
Eva van Pelt Independent Member-Supervisory Board
Ross L. Levine Independent Member-Supervisory Board
Toralf Haag Independent Member-Supervisory Board
Metin Colpan Independent Member-Supervisory Board
Eva Pisa Independent Member-Supervisory Board
Lezette Young Manager-Global Compliance
Bert van Meurs Member-Supervisory Board
Jean-Pascal Viola SVP, Head-Corporate Strategy & Business
Ulrich Schriek Senior Advisor
Thomas Theuringer Senior Director-Corporate Communications
Jonathan G. Sheldon Senior VP-Digital Insights Business Area
Antonio Santos Senior Vice President & Head-Global Operations
Stephany Foster Senior Vice President & Head-Human Resources
Thomas Schweins Senior Vice President-Life Science Business Area
Nedal Safwat VP & Head-Molecular Diagnostics North America
Philipp von Hugo VP, Head-Global Legal Affairs & Compliance
John Gilardi Vice President & Head-Investor Relations